MC2 Therapeutics A/S Sustainability Profile
MC2 Therapeutics A/S, headquartered in Denmark, is a pioneering biopharmaceutical company focused on developing innovative therapies for dermatological conditions. Founded in 2015, the company has rapidly established itself in the industry, particularly in the field of topical treatments that leverage its proprietary drug delivery technology. With a commitment to enhancing patient outcomes, MC2 Therapeutics offers unique products designed to improve the efficacy and tolerability of existing therapies. Their flagship offerings include advanced formulations that address unmet medical needs in skin health, setting them apart in a competitive market. Recognised for its scientific excellence, MC2 Therapeutics has achieved significant milestones, including successful clinical trials and partnerships that bolster its position as a leader in dermatology. The company continues to expand its operational reach, aiming to transform the landscape of skin treatment through innovation and patient-centric solutions.
DitchCarbon Score
How does MC2 Therapeutics A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MC2 Therapeutics A/S's score of 26 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MC2 Therapeutics A/S's reported carbon emissions
In 2024, MC2 Therapeutics A/S reported total carbon emissions of approximately 470,200 kg CO2e, comprising 26,200 kg CO2e from Scope 1 emissions and 444,000 kg CO2e from Scope 2 emissions. This marks an increase from 2023, when the company recorded total emissions of about 408,700 kg CO2e, with 10,700 kg CO2e from Scope 1 and 398,000 kg CO2e from Scope 2. Despite these figures, MC2 Therapeutics A/S has not established specific reduction targets or initiatives, nor do they participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The company has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. As a company headquartered in Denmark (DK), MC2 Therapeutics A/S is positioned within an industry increasingly focused on sustainability and carbon footprint reduction. However, without defined targets or commitments, their climate strategy remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 10,700 | 00,000 |
| Scope 2 | 398,000 | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is MC2 Therapeutics A/S's Industry?
How Carbon Intensive is MC2 Therapeutics A/S's Location?
MC2 Therapeutics A/S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
MC2 Therapeutics A/S has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
